2019 Investor Day presentation

ROVI updates its strategy in a meeting with shareholders, investors and analysts.


No votes yet
 
Related
Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”) has announced the purchase of Falithrom®, which was owned by Hexal AG (“Hexal”), a company...
1 min
09/01/2019
0 min
06/11/2018